首頁 > 市場調查報告書 > 製藥

生物製劑分子標靶治療學

市場調查報告書

商品編碼

1797410

雙特異性抗體藥物複合體的全球市場:臨床試驗，開發平台，競爭情形和市場機會(2025年)

Global Bispecific Antibody Drug Conjugates Clinical Trials, Development Platforms, Competitive Landscape & Market Opportunity Insight 2025

出版日期: 2025年08月01日 | 出版商:

KuicK Research | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球雙特異性抗體-藥物偶聯物市場：臨床試驗、開發平台、競爭格局和市場機會 (2025) 研究結果和亮點

預計首批雙特異性抗體-藥物偶聯物將於 2029 年上市
超過 100 種雙特異性抗體-藥物偶聯物處於臨床試驗階段
按公司、國家/地區及適應症及分階段劃分的雙特異性抗體-藥物偶聯物臨床試驗洞察
中國在全球雙特異性抗體藥物偶聯物開發領域佔主導地位：超過 60 種偶聯物
大多數用於治療癌症的雙特異性抗體-藥物偶聯物：超過 40 種
雙特異性抗體-藥物偶聯物洞察抗體-藥物偶聯物開發平台
競爭格局

雙特異性抗體-藥物偶聯物的需求及本報告的意義

雙特異性抗體-藥物偶聯物 (BsADC) 代表了癌症治療的新浪潮，它結合了雙特異性抗體的特異性與傳統抗體-藥物偶聯物 (ADC) 的靶向細胞毒性。傳統 ADC 雖然有效，但往往受到脫靶毒性和腫瘤穿透性差的影響，尤其是在實體腫瘤中。 BsADC 透過同時靶向兩種不同的抗原解決了這些問題。這種雙重標靶性可以提高腫瘤選擇性、改善藥物傳遞並減少脫靶效應。隨著技術的成熟，雙特異性抗體-藥物偶聯物可望顯著改善乳癌、肺癌和胰臟癌等難治性癌症患者的治療效果。

本報告對雙特異性抗體-藥物偶聯物進行了全面的市場分析，探討了最新的臨床試驗動態、行業領袖、技術進步以及促成這些進步的合作夥伴關係。報告還深入分析了這些改進將如何影響癌症治療的未來。

報告中臨床試驗的見解

臨床試驗在雙特異性抗體-藥物偶聯物的開發中發揮核心作用，它決定了這些新療法的安全性、有效性和耐受性。本報告分析了正在進行和即將進行的臨床試驗，並重點介紹了最有希望成為腫瘤領域下一代療法的候選藥物。例如，用於治療EGFR突變非小細胞肺癌的雙特異性ADC藥物伊沙隆單抗布倫吉康（Iza-bren），目前正處於III期臨床試驗階段，並已獲得多項突破性療法認定。本節提供的資訊具體涵蓋了臨床試驗階段、申辦者、地理分佈、技術提供者、合作方和許可證持有者。

各大公司積極參與雙特異性抗體-藥物偶聯物的研發

雙特異性抗體-藥物偶聯物市場競爭激烈，老牌製藥公司以及專業化和新興的生物技術公司都取得了長足的進步。阿斯特捷利康、安進、百時美施貴寶和信達生物等領先的研發公司正在積極開發用於治療實體瘤的雙特異性抗體-藥物偶聯物候選藥物。這些公司不僅在改進現有的抗體偶聯藥物 (ADC) 技術，還在研究新的雙特異性抗體形式，以提高特異性並減少副作用。

Duality Biotherapeutics、Allink Biotherapeutics 和江蘇康寧傑瑞等專業化公司也在緊跟步伐，專注於突破性的平台和新穎的雙特異性設計。隨著這些公司開發差異化候選藥物，雙特異性抗體-藥物偶聯物領域的競爭日益激烈，各公司競相搶佔市場，力求率先推出強效療法。

技術平台、合作與協議

雙特異性抗體-藥物偶聯物的有效性取決於尖端技術平台，這些平台能夠促進精準的抗體工程、有效的藥物偶聯以及更佳的腫瘤靶向性。像OmniAb和DualityBio這樣的公司在創建促進雙特異性抗體設計的創新平台方面處於領先地位。 OmniAb的抗體發現平台與Veraxa Biotech的ADC連接子技術的結合，反映了專注於合作的趨勢，旨在最大限度地促進雙特異性抗體-藥物偶聯物的開發。像百時美施貴寶和SystImmune這樣的策略聯盟正變得越來越普遍，各公司正在整合資源以加快開發速度。此類合作對於更快地將雙特異性抗體偶聯物推進到臨床開發階段至關重要，並且透過利用互補的技術，它們可以帶來更有效的癌症治療方案。

雙特異性抗體-藥物偶聯物市場未來發展方向報告

本報告預測雙特異性抗體-藥物偶聯物市場前景光明，技術進步和臨床成功案例的累積將推動其強勁成長。研究團隊將繼續優化雙特異性抗體-藥物偶聯物的設計，並專注於靶向腫瘤微環境中多種癌症抗原和路徑的多標靶策略。金融投資也在推動市場朝著同一方向發展，反映出投資者對雙特異性抗體-藥物偶聯物未來潛力日益增長的樂觀態度。技術進步、合作夥伴關係和資金支持的協同作用使雙特異性抗體-藥物偶聯物（BsADC）走在腫瘤學未來發展的前沿。

總體而言，隨著有前景的療法在臨床試驗中取得進展以及新技術的療效不斷提高，雙特異性抗體-藥物偶聯物市場正處於顯著增長的風口浪尖。本報告揭示了 BsADC 徹底改變癌症治療的巨大潛力，並為以前無法治療的癌症患者帶來了新的希望。

First Bispecific Antibody Drug Conjugate Availability Expected By 2029
Insight On Bispecific Antibody Drug Conjugates In clinical Trials: > 100
Bispecific Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase
China Dominating Global Bispecific Antibody Drug Conjugates Development Landscape: > 60 Conjugates
Majority Of Bispecific Antibody Drug Conjugates Cancer: > 40
Insight On Bispecific Antibody Drug Conjugates Development Platforms
Competitive Landscape

Need for Bispecific Antibody-Drug Conjugate & Why This Report?

Bispecific antibody drug conjugates (BsADCs) are a new wave in cancer treatment, fusing the specificity of bispecific antibodies with the targeted cytotoxicity of traditional antibody drug conjugates (ADCs). Whereas classic ADCs have been effective, they tend to be hampered by off-target toxicity and reduced tumor penetration, especially in solid tumors. BsADCs solve these problems through the simultaneous targeting of two distinct antigens; this dual targeting allows for enhanced tumor selectivity, improved drug delivery, and fewer off-targeting effects. Bispecific antibody drug conjugates will go on to provide significant improvements in outcomes for patients, particularly those with hard-to-treat cancers such as breast, lung, and pancreatic cancers, as the technology matures.

This report offers an comprehensive market analysis of Bispecific antibody drug conjugates, discussing the most recent clinical trial updates, industry leaders, technological advancements, and collaborative partnerships shaping progress. It also offers insight into how such improvements are expected to impact cancer treatment in the future.

Clinical Trials Insight Included In Report

Clinical trials are central to the development of Bispecific antibody drug conjugates since they establish the safety, efficacy, and tolerability of these emerging treatments. This report explores the existing trend of ongoing and future clinical trials and highlights the most promising candidates in the pipeline that have the potential to be next-generation treatments in oncology. An example of this is Izalontamab brengitecan (Iza-bren), a bispecific ADC for EGFR-mutated NSCLC, in Phase 3 trials and already received several Breakthrough Therapy Designations. The information provided in this section specifically comprises stages of trials, sponsors, geographical distribution, technology providers, collaborators and license holders.

Major Companies Active In R&D of Bispecific Antibody Drug Conjugate

Bispecific antibody drug conjugates landscape is a highly competitive market with both well-established pharmaceutical companies and specialty and startup biotechs advancing strongly. Leaders such as AstraZeneca, Amgen, Bristol Myers Squibb, and Innovent Biologics are aggressively developing Bispecific antibody drug conjugates candidates to treat solid tumors. The players are not only refining current ADC technologies but also investigation of new bispecific antibody formats to enhance specificity and decrease side effects.

Specialty firms such as Duality Biotherapeutics, Allink Biotherapeutics, and Jiangsu Alphamab Biopharmaceuticals are not far behind, with a focus on groundbreaking platforms and novel bispecific designs. As these firms develop differentiated candidates, the competition in the bispecific antibody drug conjugates arena is becoming increasingly fierce, with companies racing to make the first-to-market with very potent therapies.

Technology Platforms, Collaborations & Agreements

The efficacy of bispecific antibody drug conjugates largely rests on state-of-the-art technology platforms that facilitate accurate antibody engineering, effective drug conjugation, and improved tumor targeting. Organizations such as OmniAb and DualityBio are at the forefront of creating innovative platforms to facilitate bispecific antibody design. OmniAb's antibody discovery platform paired with Veraxa Biotech's ADC linker technology captures the trend toward focused partnerships, with the intent of maximizing bispecific antibody drug conjugates development. Strategic alliances, such as that between Bristol Myers Squibb and SystImmune, are increasingly becoming prevalent as firms share resources to speed up development. These alliances are needed for accelerating BsADCs through clinical development more quickly, leveraging complementary skills to bring more potent cancer treatments.

Report Indicating Future Direction Of Bispecific Antibody Drug Conjugate Segment

The report foresees a rosy future for the bispecific antibody drug conjugates market, with strong growth fueled by advancing technology and mounting clinical success. Researchers are likely to continue to optimize bispecific antibody drug conjugates design, with an emphasis on multi-target strategies that target multiple cancer antigens or pathways of the tumor microenvironment. Financial investments are also propelling the market in the same direction, reflecting increased investor optimism about the future of bispecific antibody drug conjugates. The synergy of technological advancement, partnering relationships, and financial support places BsADCs at the forefront of the future of oncology.

Overall, the bispecific ADC market is on the cusp of huge growth, with promising treatments advancing through clinical trials and emerging technologies improving their effectiveness. This report shines a light on the promising potential of BsADCs to revolutionize cancer treatment and bring renewed hope for patients with previously untreatable cancers.

1. Conception & Ongoing Development Of Bispecific Antibody Drug Conjugates

1.1 Overview
1.2 Comparison With Other Immunotherapies

2. Need For Bispecific Antibody Drug Conjugates

3. Bispecific Antibody Drug Conjugates - Design & Mechanism Of Action

3.1 General Structure & Design
3.2 Mechanism Of Action

4. Global Bispecific Antibody Drug Conjugate Market Insight

4.1 Current Market Scenario
4.2 Future Market Opportunity

5. Bispecific Antibody Drug Conjugates Market Analysis by Region

5.1 China
5.2 US
5.3 Europe
5.4 South Korea

6. Bispecific Antibody Drug Conjugates - Application & Development By Indication

6.1 Breast Cancer
6.2 Gastrointestinal Cancer
6.3 Lung Cancer
6.4 Urologic Cancers
6.5 Gynecologic Cancers

7. Global Bispecific Antibody Drug Conjugates Clinical Trials Overview

7.1 By Company
7.2 By Country
7.3 By Indication
7.4 By Phase

8. Bispecific Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase

8.1 Research
8.2 Preclinical
8.3 Phase I
8.4 Phase I/II
8.5 Phase II
8.6 Phase III

9. Platforms Technologies Used To Develop Bispecific Antibody Drug Conjugates

This Chapter Gives Comprehensive Insight On More Than 15 Platforms Technologies Used To Develop Bispecific Antibody Drug Conjugates

10. Competitive Landscape

10.1 Almac Discovery
10.2 Alphamab Oncology
10.3 Amgen
10.4 ArbeleBio
10.5 AstraZeneca
10.6 Beijing Biocytogen
10.7 BiVictriX Therapeutics
10.8 Bright Biologics
10.9 Corellia AI
10.10 CStone Pharmaceuticals
10.11 Debiopharm
10.12 Doma Bio
10.13 DualityBio
10.14 Enduring Biotech
10.15 Genmab
10.16 InduPro
10.17 Innovent Biologics
10.18 Kanaph Therapeutics
10.19 ProEn Therapeutics
10.20 Synaffix

簡介目錄圖表

List of Figures

Figure 1-1: Future Directions In BsADC Development
Figure 1-2: Limitations Of Convectional Immunotherapies Addressable By BsADCs
Figure 3-1: Bispecific Antibody Drug Conjugate - General Structure
Figure 3-2: Bispecific Antibody Drug Conjugate - General Mechanism of Action
Figure 4-1: Bispecific Antibody Drug Conjugate Market forecast - Projections For First 12 & 24 Months Post-Approval Of First Drug (US$ Million)
Figure 4-2: Key Future Opportunities
Figure 6-1: BL-B01D1-306 Phase III (NCT06343948) Study - Initiation & Estimated Completion Year
Figure 6-2: BL-B01D1-307 Phase III (NCT06382142) Study - Initiation & Estimated Completion Year
Figure 6-3: BL-B01D1-204-04 Phase II (NCT06471205) Study - Initiation & Estimated Completion Year
Figure 6-4: BL-B01D1-SI-B003-201-04 Phase II (NCT06042894) Study - Initiation & Estimated Completion Year
Figure 6-5: BL-B01D1-LUNG-101 Phase I (NCT05983432) Study - Initiation & Estimated Completion Year
Figure 6-6: BL-B01D1-104 Phase I (NCT05470348) Study - Initiation & Estimated Completion Year
Figure 6-7: KM501-1001 Phase I (NCT05804864) Study - Initiation & Estimated Completion Year
Figure 6-8: BL-B01D1-SI-B003-201-05 Phase II (NCT06008054) Study - Initiation & Estimated Completion Year
Figure 6-9: BL-B01D1-103 Phase I (NCT05262491) Study - Initiation & Estimated Completion Year
Figure 6-10: BL-B01D1-302 Phase III (NCT06382129) Study - Initiation & Estimated Completion Year
Figure 6-11: BL-B01D1-301 Phase III (NCT06382116) Study - Initiation & Estimated Completion Year
Figure 6-12: BL-B01D1-304 Phase III (NCT06500026) Study - Initiation & Estimated Completion Year
Figure 6-13: DM001001 Phase II (NCT06475937) Study - Estimated Initiation & Estimated Completion Year
Figure 6-14: CIBI334A101 Phase I/II (NCT05774873) Study - Estimated Initiation & Estimated Completion Year
Figure 6-15: BL-B01D1-201 Phase II (NCT05785039) Study - Initiation & Estimated Completion Year
Figure 6-16: BL-B01D1-102 Phase I (NCT05393427) Study - Initiation & Estimated Completion Year
Figure 6-17: BL-B01D1-SI-B003-201-08 Phase II (NCT05990803) Study - Initiation & Estimated Completion Year
Figure 6-18: BL-B01D1-202 Phase Ib/II (NCT05803018) Study - Initiation & Estimated Completion Year
Figure 6-19: IMGN151-1001 Phase I (NCT05527184) Study - Initiation & Estimated Completion Year
Figure 6-20: JSKN003-102 Phase I/II (NCT05744427) Study - Initiation & Estimated Completion Year
Figure 7-1: Global - Bispecific Antibody Drug Conjugates Clinical Pipeline By Company (Numbers), 2025
Figure 7-2: Global - Bispecific Antibody Drug Conjugates Clinical Pipeline By Country (Numbers), 2025
Figure 7-3: Global - Bispecific Antibody Drug Conjugates Clinical Pipeline By Indication (Numbers), 2025
Figure 7-4: Global - Bispecific Antibody Drug Conjugates Clinical Pipeline By Phase (Numbers), 2025
Figure 9-1: ArbeleBio - Unnamed ADC Platform
Figure 9-2: BiVictriX - Bi-Cygni Therapeutics
Figure 9-3: Duality Biologics - DITAC Platform
Figure 9-4: Duality Biologics - DITAC Platform
Figure 9-5: LigaChem Biosciences - ConjuALL
Figure 9-6: LigaChem Biosciences - Conjugation Method
Figure 9-7: LigaChem Biosciences - B-Glucuronide Linker
Figure 9-8: LigaChem Biosciences - B-Glucuronide Linker
Figure 9-9: ProEn Therapeutics - ArtBody(TM) ADC technology
Figure 9-10: Synaffix - Proprietary Technologies